AstraZeneca is making a bigger push into the companion diagnostics space. The pharmaceutical company is teaming up with Shanghai, China-based Amoy Diagnostics to develop assays.
The companies are working on two initial projects. The first is the co-development of a CDx to identify prostate cancer patients with Homologous Recombination Repair (HRR) gene mutations in China, the EU and Japan.
The next project is the development of a CDx to identify breast cancer patients with BRCA gene mutations in the EU for Lynparza (olaparib) monotherapy.
Li-Mou Zheng, PhD, Founder and Chairman of AmoyDx, said, “We are very pleased to announce today that we are further developing our partnership with AstraZeneca by entering into a master collaboration agreement. AmoyDx is a trustworthy CDx co-development partner with rich expertise in R&D, Regulatory Affairs and Commercialization globally. AmoyDx and AstraZeneca share the common core value of prioritizing patients, and we will work together to accelerate the contribution for the benefit of patients.”
